Why a fundamental rethinking of how manufacturers engage with healthcare providers, payers, and patients is necessary in today's pharma landscape.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

Odylia Therapeutics event brings together leaders across biotech, pharma, venture capital, patient advocacy, and research ...

Nigel McCracken, chief operating officer, Virax Biolabs, discusses results from new data on the role of T cell dysfunction in post-acute infection syndromes.

Sales challenges were also at the forefront of Salesforce’s "State of Sales Report 2024 2 " which surveyed over 5,500 sales professionals and identified that the number one top priority for sales ...

Despite meeting key pharmacokinetic goals, a potential case of drug-induced liver injury led Pfizer to conclude that danuglipron’s risk-benefit profile did not support further development for chronic ...